Table 2 Outcomes
From: Impact of dexamethasone in severe COVID-19-induced acute kidney injury: a multicenter cohort study
All patients (n = 798) | Non DXM (n = 331) | DXM (n = 467) | p value | |
|---|---|---|---|---|
Acute kidney injury*, n (%) | 598 (75%) | 282 (85%) | 316 (67%) | < 0.001 |
Defined using SCr, n (%) | 345 (58%) | 198 (70%) | 147 (47%) | < 0.001 |
Defined using diuresis criterion, n (%) | 552 (92%) | 249 (88%) | 303 (96%) | 0.030 |
AKI Stage 1, n (%) | 225 (38%) | 100 (35%) | 125 (40%) | 0.287 |
AKI Stage 2, n (%) | 163 (27%) | 73 (26%) | 90 (28%) | 0.337 |
AKI Stage 3, n (%) | 210 (35%) | 109 (39%) | 101 (32%) | 0.001 |
Renal replacement therapy, n (%) | 61 (10%) | 41 (15%) | 20 (6%) | < 0.001 |
SCr at admission (µmol/L), median [IQR] (missing values, n = 94) | 73 [58–95] | 79 [63–110] | 69 [56–86] | < 0.01 |
Length of intubation (days), median [IQR] | 12 [6–20] | 13 [6–22] | 13 [7–21] | 0.6 |
Length of sedation (days), median [IQR] | 10 [3–18] | 10 [3–19] | 8 [3–17] | 0.13 |
ICU length of stay (days), median [IQR] | 9 [5–19] | 11 [5–24] | 8 [4–17] | < 0.01 |
ICU death, n (%) | 208 (26%) | 109 (33%) | 99 (21%) | < 0.001 |